Donald W Kufe

This inventor holds 60 USPTO granted patents and 29 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Cancer Immunotherapy (CPC class A61K). Top assignees: Dana-Farber-Cancer Institute Inc., Genus Oncology, LLC, Arch Development Corporation. Active years: 1990-2025.

USPTO Granted Patents = 60 (Patent Applications = 29)

% Patents Active = 78.3

CIPO Patents = 4 (Patent Applications = 16)

EPO Patents = 8 (Patent Applications = 22)

Average Co-Inventor Count = 2.0

ph-index = 12

Forward Citations = 461(Granted Patents)

Forward Citations (Not Self Cited) = 374(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

49 out of 1,266

Dana-Farber-Cancer Institute Inc.

Arch Development Corporation

patents

4. 7 out of 964

The University of Chicago

patents

5. 1 out of 31

Adherex Technologies, Inc.

Beth Israel Deaconess Medical Center, Inc.

Hillstream Biopharma, Inc.

patents

10. 1 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

11. 1 out of 15

Therion Biologics Corporation

patents

12. 1 out of 1

Xyone Therapeutics Inc.

patent

13. 4 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

MUC1 Antibodies

Cancer Therapy

Polymeric Nanoparticles

Combination Therapies

Inflammation Inhibition

Gene Therapy

Small Molecule Inhibitors

MUC1 Peptides

Apoptosis Regulation

Tumor-Associated Antigens

Caspase-8

Dendritic Cell Hybrids

60 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466895 - ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) (2025-11-11),

2. 11484507 - Polymeric nanoparticles providing nucleic acids encoding TNF-α (2022-11-01),

3. 11136410 - Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) (2021-10-05),

4. 11026921 - Compositions and methods of treating cancer (2021-06-08),

5. 10617773 - Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) (2020-04-14),

6. 10059775 - Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) (2018-08-28),

7. 9789156 - Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics (2017-10-17),

8. 9663562 - Compositions and methods for treating cancer (2017-05-30),

9. 9572855 - Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics (2017-02-21),

10. 9546201 - MUC-1 cytoplasmic domain peptides as inhibitors of cancer (2017-01-17),

11. 9096687 - Inhibition of inflammation using antagonists of MUC1 (2015-08-04),

12. 9044421 - Treating MUC1-expressing cancers with combination therapies (2015-06-02),

13. 8957185 - MUC-1 cytoplasmic domain peptides as inhibitors of cancer (2015-02-17),

14. 8952054 - Small molecule inhibitors of MUC1 and methods of identifying the same (2015-02-10),

15. 8809002 - MUC1, caspase-8, and DED-containing proteins (2014-08-19),

Certainly! Here's the article about inventor Donald W Kufe:

Title: The Innovator Extraordinaire: Donald W Kufe

Introduction: Donald W Kufe, a talented inventor hailing from Wellesley, MA, has left an indelible mark on the world of patents with his impressive portfolio of 59 patents.

Latest Patents:

1. **Polymeric Nanoparticles Providing Nucleic Acids Encoding TNF-α:** Kufe's groundbreaking invention involves polymeric nanoparticles containing a cytokine or nucleic acid encoding for a cytokine, paving the way for innovative pharmaceutical compositions and treatment methods for various diseases.

2. **Antibodies Against the MUC1-C/Extracellular Domain (MUC1-C/ECD):** Another feather in Kufe's cap, this invention focuses on antibodies binding to MUC1-C/extracellular domain, offering promising avenues for treating cancers expressing the MUC1 antigen.

Career Highlights:

Throughout his illustrious career, Donald W Kufe has lent his inventive prowess to renowned companies in the industry. Notably, he has contributed significantly to Dana-Farber-Cancer Institute Inc. and Genus Oncology, LLC.

Collaborations:

In his journey towards innovation, Kufe has had the privilege of working alongside esteemed colleagues such as Ralph R Weichselbaum and Surender Kharbanda, fostering a collaborative environment rich in creativity and expertise.

Conclusion:

Donald W Kufe's exceptional contributions to the field of patents stand as a testament to his unwavering dedication to innovation. With a plethora of patents under his belt and a stellar career marked by fruitful collaborations, Kufe continues to inspire the budding inventors of tomorrow with his trailblazing work.

Is there anything else you would like to know about Donald W Kufe or any other inventor in the realm of innovations and patents?